hydralazine hydrochloride
hydralazine hydrochloride
CLINICAL USE
Vasodilator antihypertensive agent
DOSE IN NORMAL RENAL FUNCTION
Oral: Hypertension: 25–50 mg twice daily; —maximum daily dose 100 mg in women and slow acetylators, 200 mg in fast acetylatorsHeart failure: 25–75 mg 3–4 times daily —IV: slow IV injection: 5–10 mg over 20 minutes; repeat after 20–30 minutes if necessaryInfusion: 200–300 micrograms/minute initially, reducing to 50–150 micrograms/minute
PHARMACOKINETICS
Molecular weight                           :196.6 %Protein binding                           :87 %Excreted unchanged in urine     : 2–14 Volume of distribution (L/kg)       :0.5–0.9half-life – normal/ESRD (hrs)      :2–4/16 DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Start at low dose and adjust in accordance with response 10 to 20     : Start at low dose and adjust in accordance with response <10           : Start at low dose and adjust in accordance with response DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in GFR <10 mL/min HD                     :Not dialysed. Dose as in GFR <10 mL/min HDF/high flux   :Not dialysed. Dose as in GFR <10 mL/minCAV/VVHD      :Not dialysed. Dose as in GFR=10–20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs Anaesthetics: increased hypotensive effects ADMINISTRATION
Reconstition
20 mg with 1 mL water for injection then dilute with 10 mL sodium chloride 0.9% for IV injection or 500 mL sodium chloride 0.9% for IV infusion
Route
Oral, IV peripherally Rate of Administration
As above Comments
Minimum volume of 60 mg in 60 mL. OTHER INFORMATION
Avoid long-term use in severe renal insufficiency and dialysis patients, due to accumulation of metaboliteshydralazine hydrochloride.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home